Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 4,188 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Upper Extremity Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Shatavari Root Extract in Women's Sexual Wellness

NCT07441083
View directory record Official record
Conditions
Sexual Wellness, Women Health
Interventions
Shatavari (Asparagus racemosus) Root Extract, Placebo Capsule
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
20 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Non-Invasive Imaging for Cording in Breast Cancer Patients

NCT01427166
View directory record Official record
Conditions
Breast Cancer
Interventions
Non invasive venous ultrasound
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors

NCT02366312
View directory record Official record
Conditions
Keratocystic Odontogenic Tumor
Interventions
vismodegib
Drug
Lead sponsor
NYU College of Dentistry
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 26, 2026, 2:59 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

NCT07228403
View directory record Official record
Conditions
Short Bowel Syndrome (SBS)
Interventions
Glepaglutide 10 mg
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Rochester, Minnesota • Omaha, Nebraska • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

NCT03475186
View directory record Official record
Conditions
Glioblastoma, Radiotherapy; Complications, Cognitive Decline, Chemoradiation
Interventions
Ramipril
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
422
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 280 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

NCT02635724
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Brooksville, Florida • Lakeland, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Ideal Steroids for Asthma Treatment in the PICU

NCT03900624
View directory record Official record
Conditions
Asthma Childhood
Interventions
Dexamethasone
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

NCT01841762
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 26, 2026, 2:59 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

NCT05699603
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Biopsy, Calcipotriene, Fluorouracil
Procedure · Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Tucson, Arizona • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 26, 2026, 2:59 AM EDT
Active, not recruiting Phase 2 Interventional

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

NCT03546686
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery, Ipilimumab, Nivolumab
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Columbus, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 26, 2026, 2:59 AM EDT
Recruiting Phase 4 Interventional

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

NCT06952660
View directory record Official record
Conditions
Cervical Cancer
Interventions
TIVDAK
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
131
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Phase 3 Interventional Results available

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT05468320
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Corticosteroids, anti-CD20 antibody
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT03589469
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
Interventions
Loncastuximab tesirine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
24
States / cities
Duarte, California • Fountain Valley, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 26, 2026, 2:59 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

NCT05644561
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 26, 2026, 2:59 AM EDT
Not listed Not applicable Interventional

Assessing the Performance of Wesper Lab for Sleep Apnea Diagnosis in Pediatric Populations

NCT06218186
View directory record Official record
Conditions
Sleep Apnea, Sleep Apnea Syndromes in Children, Sleep Apnea Syndromes
Interventions
Medical Device: Wesper Lab Home Sleep Test
Device
Lead sponsor
Wesper Inc
Industry
Eligibility
2 Years to 21 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Edmond, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 26, 2026, 2:59 AM EDT
Enrolling by invitation No phase listed Observational

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

NCT05718570
View directory record Official record
Conditions
Adult Growth Hormone Deficiency
Interventions
Somapacitan
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Evaluate the Safety, Functionality, and the Quality of Life of Patients Who Receive the Freedom Total Knee ® System

NCT02056470
View directory record Official record
Conditions
Knee Joint Pain
Interventions
Freedom Total Knee, Total Knee Replacement, Freedom Total Knee System
Device
Lead sponsor
Maxx Orthopedics Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function

NCT06012669
View directory record Official record
Conditions
Immune Health
Interventions
High dose Human Lactoferrin, Low dose Human Lactoferrin, Active Control Bovine Lactoferrin
Dietary Supplement
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Miami, Florida • Port Saint Lucie, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 26, 2026, 2:59 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

NCT07052682
View directory record Official record
Conditions
Steatohepatitis
Interventions
Ontamalimab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 26, 2026, 2:59 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hormones, Outcomes, and Pain Pathways in Exercise Study

NCT07579182
View directory record Official record
Conditions
Breast Pain, Mastalgia, Back Pain, Back Pain, Low, Neck Pain, Chest Pain, Activity, Motor, Healthy Aging, Weight, Body, Inflammation, Gonadal Steroid Hormones, Neuronal Plasticity, Neuromuscular Manifestations
Interventions
Interventional Sports bra
Other
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects

NCT04621318
View directory record Official record
Conditions
Healthy
Interventions
Denosumab
Drug
Lead sponsor
Samsung Bioepis Co., Ltd.
Industry
Eligibility
28 Years to 55 Years · Male only
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 26, 2026, 2:59 AM EDT
Completed No phase listed Observational Results available

Pediatric Distal Radius US Study

NCT01937624
View directory record Official record
Conditions
Distal Radius Fractures
Interventions
Diagnostic Ultrasound, X-ray imaging
Device · Radiation
Lead sponsor
The Hawkins Foundation
Other
Eligibility
2 Years to 15 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

NCT04701918
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Bladder Cancer
Interventions
Pembrolizumab, Cryoablation, Avelumab
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 26, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

NCT02384382
View directory record Official record
Conditions
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Detroit, Michigan • Farmington Hills, Michigan • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 26, 2026, 2:59 AM EDT